Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pediococcus pentosaceus Li05
- Development stage
- Preclinical
- Lead developer
- Zhejiang University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pediococcus pentosaceus Li05 (registered as CGMCC 7049) is a live biotherapeutic product (LBP) consisting of a specific probiotic bacterial strain originally isolated from the fecal samples of a healthy human volunteer. Primarily investigated by academic and clinical research groups in China, such as those at Zhejiang University, Li05 has demonstrated significant anti-inflammatory, antioxidant, and lipid-lowering properties in preclinical models. Its therapeutic mechanism involves the modulation of the gut microbiota composition, preservation of intestinal epithelial barrier integrity, and regulation of key signaling pathways including the 5-HT (serotonin) pathway and the FXR-mediated bile acid signaling axis (FXR-SHP/FXR-FGF15). It is currently under research for the treatment of various gastrointestinal and hepatic conditions, including inflammatory bowel disease (IBD), Clostridium difficile infection (CDI), and primary sclerosing cholangitis (PSC).
- Other names
- Pediococcus pentosaceus Li05P. pentosaceus Li05
02
Targets
FXR (Farnesoid x-activated receptor)HTR3B (5-hydroxytryptamine receptor 3B)
Beyond the preview
Go deeper on Pediococcus pentosaceus Li05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pediococcus pentosaceus Li05.